ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Action Plan Committee Outrages By Plans for $14M In NCI Funds

August 1, 1997

Newell Reports Cancer Deaths In Younger Age Groups Dropping

March 18, 1977

Crout Resigns As Director Of FDA Drugs Bureau

July 11, 1980

FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions

January 28, 2011

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

SWOG Closes Prostate Cancer Trial With Mitoxantrone

February 23, 2007